Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Maintains $300 Price Target
ALNYMarch 21, 2025
Read more →Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target
ALNYMarch 21, 2025
Read more →Alnylam Secures FDA Approval Of sNDA For Its RNAi Therapeutic, AMVUTTRA, For Treatment Of ATTR-CM In Adults To Reduce Cardiovascular Mortality, Cardiovascular Hospitalizations And Urgent Heart Failure Visits
ALNYMarch 20, 2025
Read more →How Do Investors Really Feel About Alnylam Pharmaceuticals?
ALNYMarch 14, 2025
Read more →Demystifying Alnylam Pharmaceuticals: Insights From 15 Analyst Reviews
ALNYMarch 11, 2025
Read more →JP Morgan Maintains Neutral on Alnylam Pharmaceuticals, Raises Price Target to $280
ALNYMarch 11, 2025
Read more →$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
ALNYMarch 3, 2025
Read more →Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years
ALNYFebruary 26, 2025
Read more →RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $310 Price Target
ALNYFebruary 26, 2025
Read more →Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Maintains $300 Price Target
ALNYFebruary 26, 2025
Read more →Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target
ALNYFebruary 26, 2025
Read more →HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $500
ALNYFebruary 25, 2025
Read more →HC Wainwright & Co. Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $500
ALNYFebruary 24, 2025
Read more →Coinbase To Rally Over 11%? Here Are 10 Top Analyst Forecasts For Tuesday
ALNYFebruary 18, 2025
Read more →Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $385
ALNYFebruary 18, 2025
Read more →Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Raises Price Target to $284
ALNYFebruary 14, 2025
Read more →Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target
ALNYFebruary 14, 2025
Read more →Alnylam Sees 2024 Total TTR Net Product Revenues $1.6B-$1.725B
ALNYFebruary 13, 2025
Read more →Alnylam Pharmaceuticals Q4 2024 Adj. EPS $0.06, Sales $593.166M Beat $583.791M Estimate
ALNYFebruary 13, 2025
Read more →$1000 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
ALNYJanuary 13, 2025
Read more →HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target
ALNYJanuary 13, 2025
Read more →What 15 Analyst Ratings Have To Say About Alnylam Pharmaceuticals
ALNYJanuary 13, 2025
Read more →Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target
ALNYJanuary 13, 2025
Read more →Reported Earlier, Alnylam Pharmaceuticals Preliminary Results: $1.6B In 2024 Net Product Revenue (+33% YoY); 2025 Revenue Guidance Of $2.05B–$2.25B, And Highlights Key Pipeline Goals
ALNYJanuary 13, 2025
Read more →How Is The Market Feeling About Alnylam Pharmaceuticals?
ALNYDecember 24, 2024
Read more →GIVLAARI Gains Nationwide Reimbursement In Canada For Treating Acute Hepatic Porphyria
ALNYDecember 23, 2024
Read more →Piper Sandler Reiterates Overweight on Alnylam Pharmaceuticals, Maintains $296 Price Target
ALNYNovember 18, 2024
Read more →HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target
ALNYNovember 18, 2024
Read more →Reported Sunday, Alnylam Reported Interim Phase 1 Results For Nucresiran (ALN-TTRsc04), Demonstrating Rapid And Sustained TTR Reduction Lasting Six Months After A Single Dose
ALNYNovember 18, 2024
Read more →Deep Dive Into Alnylam Pharmaceuticals Stock: Analyst Perspectives (24 Ratings)
ALNYNovember 4, 2024
Read more →HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target
ALNYNovember 4, 2024
Read more →Raymond James Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $298
ALNYNovember 1, 2024
Read more →RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $300 Price Target
ALNYNovember 1, 2024
Read more →Scotiabank Maintains Sector Outperform on Alnylam Pharmaceuticals, Raises Price Target to $310
ALNYNovember 1, 2024
Read more →Barclays Maintains Overweight on Alnylam Pharmaceuticals, Raises Price Target to $329
ALNYNovember 1, 2024
Read more →Canaccord Genuity Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $384
ALNYNovember 1, 2024
Read more →Chardan Capital Maintains Buy on Alnylam Pharmaceuticals, Maintains $300 Price Target
ALNYNovember 1, 2024
Read more →Needham Reiterates Buy on Alnylam Pharmaceuticals, Maintains $320 Price Target
ALNYNovember 1, 2024
Read more →(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
ALNYOctober 31, 2024
Read more →Alnylam Pharmaceuticals Reiterated 2024 Financial Guidance, Including Combined Net Product Revenues Of $1.575B-$1.65B
ALNYOctober 31, 2024
Read more →Alnylam Pharmaceuticals Q3 2024 Adj EPS $(0.50) Beats $(0.93) Estimate, Sales $500.92M Miss $533.10M Estimate
ALNYOctober 31, 2024
Read more →(ALNY) - Analyzing Alnylam Pharmaceuticals's Short Interest
ALNYMay 17, 2024
Read more →Why Alnylam Pharmaceuticals Shares Are Falling
ALNYAlnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares are trading lower by 4.97% to $212.18 Monday morning after the company announced a proposed offering of $900 million convertible
September 12, 2022
Read more →Alnylam Announces Proposed Offering Of $900M Convertible Senior Notes
ALNYSeptember 12, 2022
Read more →Where Alnylam Pharmaceuticals Stands With Analysts
ALNYWithin the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) has observed the following analyst ratings:
September 9, 2022
Read more →Analyst Ratings for Alnylam Pharmaceuticals
ALNYAnalysts have provided the following ratings for Alnylam Pharmaceuticals (NASDAQ:ALNY) within the last quarter:
September 9, 2022
Read more →Oppenheimer Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $256
ALNYSeptember 9, 2022
Read more →Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $222
ALNYSeptember 9, 2022
Read more →BMO Capital Maintains Market Perform on Alnylam Pharmaceuticals, Raises Price Target to $200
ALNYSeptember 9, 2022
Read more →Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
ALNYSeptember 8, 2022
Read more →